Eli Lilly Reports Strong Q1 Earnings with 56% Revenue Growth Driven by GLP-1 Drug Sales
Eli Lilly (LLY) stock rose nearly 10% following Q1 earnings, driven by a 56% year-over-year revenue increase, largely due to strong sales of its GLP-1 drugs Zepbound and Mounjaro. Zepbound revenue grew 80% to $4.16 billion, while Mounjaro revenue surged 125% to $8.66 billion. The FDA's approval of Foundayo, a new GLP-1 pill, also contributed to the positive performance.
Tickers: $LLY
Topics: Earnings FDA Approval GLP-1 Drugs Pharmaceuticals Stock Price Movement